Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer

Complete title: Evaluation of CT Perfusion Parameters as a Potential Biomarker for Pancreatic Cancer

Research Study Number 9625
Principal Investigator Ryan O'Malley
Phase Pilot

Research Study Description

This pilot clinical trial studies how well computed tomography (CT) perfusion images work in assessing treatment response in patients with pancreatic cancer. Analyzing specific measurements on the CT perfusion images may help doctors better determine how a tumor responds to chemotherapy and/or radiation therapy and may help guide treatment for patients with pancreatic cancer.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older (Adult, Senior)

Sexes Eligible for Study: All

- Signed informed consent form

- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients unable to provide informed consent

- Women who are pregnant or intending to become pregnant during the study

- Patients with body mass index greater than 40 kg/m^2

- History of severe allergic-like reaction to iodinated contrast media

Other exclusion criteria may apply.

Research Study Number 9625
Contact Ryan O'Malley
Telephone 206/598-0024

Keywords: Pancreatic Cancer; Solid Tumors; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Endocrine Gland Neoplasms; Digestive System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials